source
- Biotech crossover rounds projected to exceed $4.2 billion in 2026, supporting IPO pipelinePitchBook forecasts that biotech crossover rounds could surpass $4.22 billion across roughly 28 rounds in 2026. The surge follows a market bottom after COVID and a rise in investor confidence, wit…
- BioSpace launches dashboard to track performance of U.S. biotech IPOs in 2026BioSpace introduced a new IPO dashboard that monitors U.S. biotech companies that went public in 2026. The tool will be refreshed weekly with the latest closing prices and will add any newly liste…